Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood cancer journal Clay-Gilmour, A. I., Rishi, A. R., Goldin, L. R., Greenberg-Worisek, A. J., Achenbach, S. J., Rabe, K. G., Maurer, M. J., Kay, N. E., Shanafelt, T. D., Call, T. G., Brice Weinberg, J., Camp, N. J., Cerhan, J. R., Leis, J., Norman, A., Murray, D. L., Vincent Rajkumar, S., Caporaso, N. E., Landgren, O., McMaster, M. L., Slager, S. L., Vachon, C. M. 2019; 9 (8): 59

Abstract

Chronic lymphocytic leukemia (CLL) and its precursor, monoclonal B-cell lymphocytosis (MBL), are heritable. Serumfree light-chain (sFLC) measures are a prognostic factor for CLL, but their role in susceptibility to CLL is not clear. We investigated differences between sFLC measurements in pre-treatment serum from five groups to inform the association of sFLC with familial and sporadic CLL: (1) familial CLL (n=154), (2) sporadic CLL (n=302), (3) familial MBL (n=87), (4) unaffected first-degree relatives from CLL/MBL families (n=263), and (5) reference population (n=15,396). The percent of individuals having elevated monoclonal and polyclonal sFLCs was compared using age-stratified and age- and sex-adjusted logistic regression models. In age groups >50 years, monoclonal sFLC elevations were increased in sporadic and familial CLL cases compared to the reference population (p's<0.05). However, there were no statistically significant differences in sFLC monoclonal or polyclonal elevations between familial and sporadic CLL cases (p's>0.05). Unaffected relatives and MBL cases from CLL/MBL families, ages >60 years, showed elevated monoclonal sFLC, compared to the reference population (p's<0.05). This is the first study to demonstrate monoclonal sFLC elevations in CLL cases compared to controls. Monoclonal sFLC levels may provide additional risk information in relatives of CLL probands.

View details for DOI 10.1038/s41408-019-0220-x

View details for PubMedID 31383849